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ABSTRACT
Objective FUS gene mutations were recently identified in
familial amyotrophic lateral sclerosis (ALS). The present
studies sought to define the clinical, post-mortem and
neurophysiological phenotypes in ALS families with FUS
mutations and to determine the frequency of FUS
mutations in familial and sporadic ALS.
Methods FUS was screened for mutations in familial
and sporadic ALS cases. Clinical, post-mortem and
neurophysiological features of large families with FUS
mutations are described.
Results and conclusions FUS mutations were evident
in 3.2% (4/124) of familial ALS, representing the second
most common gene abnormality to be described in
familial ALS after SOD1. No mutations were present in
247 sporadic ALS cases. The clinical presentation in 49
affected patients was consistent with a predominantly
lower motor neuron disorder, supported by post-mortem
findings. Upper motor neuron involvement varied, with
Wallerian degeneration of corticospinal tracts present in
one post-mortem case but absent in a second case from
the same family. Features of cortical hyperexcitability
demonstrated upper motor neuron involvement
consistent with other forms of familial and sporadic ALS.
One case presented with frontotemporal dementia (FTD)
indicating that this may be a rare presenting feature in
families with FUS mutation. Ubiquitin-positive
cytoplasmic skein-like inclusions were present in lower
motor neurons, but in contrast to sporadic ALS, no TDP-
43 pathology was evident. Mutation-specific clinical
features were identified. Patients with a R521C mutation
were significantly more likely to develop disease at
a younger age, and dropped-head syndrome was
a frequent feature. Reduced disease penetrance was
evident among most affected families.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) leads to paral-
ysis of voluntary muscles due to the progressive
death of motor neurons in the brain and spinal
cord.1 2 ALS typically results in death within
3e5 years of ﬁrst symptoms, usually related to
respiratory complications. A proportion of patients
may also develop clinical or subclinical fronto-
temporal dementia (FTD). The incidence of ALS in
the population is around 1e2 per 100 000 and
prevalence 4e6 per 100 000.3 Ubiquitination of
misfolded proteins that aggregate in affected cells
are pathological hallmarks of ALS and FTD.
Misfolded TAR DNA-binding protein (TDP-43),
which is involved in mRNA processing, is a prin-
cipal component of these ubiquitin-positive inclu-
sions in about 90% of cases.4e6
Approximately 10% of ALS cases have a positive
family history (familial ALS) and appear clinically
indistinguishable from sporadic ALS cases. Of these
familial cases, 10e20% are caused by mutations in
the superoxide dismutase 1 gene (SOD1).7 8 The
TARDBP gene, which encodes TDP-43, was also
conﬁdently linked to familial ALS, and rare muta-
tions in this gene have now been described in both
familial and sporadic ALS cases.9e11 Mutations in
the angiogenin (ANG) and dynactin (DCTN1)
genes have also been reported in a small number of
ALS cases. A mutation in the VAPB gene has been
described in several families with atypical ALS
linked to chromosome 20, although only one indi-
vidual had classic ALS, and remaining individuals
showed spinal muscular atrophy (SMA).12 Muta-
tions in the CHMP2B gene have been reported in
a small number of atypical ALS cases,13 but analysis
of classic ALS cohorts suggest that this gene is not
a common cause of familial or sporadic ALS.14
Other ALS loci have been identiﬁed on chromo-
somes 18q21 and 20q13 with no discrete genes
identiﬁed to date. Families with ALS-FTD have also
been linked to chromosome 9.8
More recently, mutations in the fused in sarcoma
gene (FUS, also known as translocated in lipo-
sarcoma, TLS), an RNA-processing gene that is
functionally related to TARDBP, were identiﬁed in
large ALS families linked to chromosome 16q12.15 16
Mutations were also identiﬁed in several small ALS
families and apparent sporadic cases supporting the
pathogenic role of mutations in this gene.11 17e20
The present study was undertaken to establish
the frequency of FUS mutations in familial and
sporadic ALS patients. In addition, the clinical,
post-mortem and neurophysiological phenotypes in
several large multigenerational families with FUS
mutations are described for the ﬁrst time.
METHODS
Subjects
Australian ALS families were ascertained through
neurogenetic clinics at Concord Hospital, Sydney,
and the Molecular Medicine Laboratory, Concord
Hospital, a referral centre for SOD1 DNA diag-
nostic testing. Two hundred and forty-seven
Australian sporadic ALS cases were obtained from
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predominantly of European descent. A clinical diagnosis of
deﬁnite or probable ALS was based on the ﬁndings of neuro-
logical examination, particularly the development of progressive
wasting and weakness. ALS families included in FUS mutation
analysis were previously screened and shown to be negative for
genes SOD1, TARDBP, ANG, DCTN1, VEGF and CHMP2B.
Patients and family members provided informed written
consent in accordance with protocols approved by the human
research ethics committee of the Sydney South West Area
Health Service.
Genetic analysis
Genomic DNA was extracted from the peripheral blood
of family members and genotyped using standard methods.
Two-point and multipoint linkage analysis was performed as
previously described.10
Mutation screening
All exons and at least 100 bp of ﬂanking intronic sequence of
FUS were ampliﬁed by the PCR and sequenced using Big-Dye
terminator sequencing and ABI 3730XL automated sequencer
(Applied Biosystems, Foster City, California). Sequencing
primers were the same as those used in PCR ampliﬁcation.
Primers and ampliﬁcation conditions are available from the
authors on request.
Cortical excitability testing
Cortical excitability was assessed by applying transcranial
magnetic stimulation (TMS) to the motor cortex by means of
a 90 mm circular coil, with currents generated by two high-
power magnetic stimulators which were connected via a BiStim
device (Magstim Co., Whitland, UK). A threshold tracking
paradigm was applied to record the resting motor threshold
(RMT) and short interval intracortical inhibition (SICI) as
previously described.21 In addition, single stimulus TMS was
used to record stimulus response (SR) curves, central motor
conduction time (CMCT) and cortical silent period (CSP)
duration.
Compound muscle action potential (CMAP) and motor-
evoked potential (MEP) recordings were obtained as previously
described.22
Immunostaining
The following antisera were used for immunohistochemistry:
rabbit polyclonal antibodies to Ubiquitin (Dako, Carpentaria,
California) and TDP-43 (Proteintech Group, Chicago, Illinois),
using a standard streptavidin-biotinylated immunoperoxidase
technique. In brief, sections were dewaxed using xylene and
rehydrated through alcohols, and antigen retrieval was
performed using citrate buffer (pH 6) for Ubiquitin and EDTA
(pH 8) for TDP-43. Slides were washed twice in PBS (pH 7.4),
and then endogenous peroxidise activity was quenched. Non-
speciﬁc proteins were blocked using normal horse serum for
20 min. Either antibody was applied at 1:4000 at room
temperature overnight. Sections were washed twice in PBS, and
then a biotinylated antirabbit secondary (Vector Laboratories,
Burlingame, California) was applied for 60 min at room
temperature. Following two PBS washes, slides were incubated
for 1 h at room temperature with a streptavidin-conjugated
peroxidase tertiary (Pierce, Rockford, Illinois). Sections were
visualised using diaminobenzidine tetrahydrochloride (DAB),
washed, counterstained with haematoxylin, dehydrated, cleared
and mounted on glass slides.
Statistical analysis
Age-dependent penetrance distributions were compared by
constructing contingency tables and performing a c2 analysis.
All other statistical analyses of clinical data were performed
using an unpaired t test. A two-tailed p value was calculated
with the nominal a value set at 0.05. Tests were performed using
GraphPad software (http://www.graphpad.com).
Cortical excitability studies in two patients with FUS muta-
tions were compared with data from 55 normal controls (28
men; 23e73 years, mean: 46 years) and 53 clinically probable or
deﬁnite sporadic ALS patients, deﬁned according to the revised El
Escorial criteria23 (34 men; 26e71 years, mean 59 years). Results
are expressed as mean6SE of the mean.
RESULTS
Mutation analysis
The overall ALS cohort comprised 124 ALS families and 247
sporadic ALS cases. Twenty-one of the ALS families were
previously shown to carry SOD1 mutations through our role as
a referral centre for SOD1 DNA diagnostic testing. A subset of
ALS families were previously screened for FUS mutations with
three positive families identiﬁed.15 To complete analysis of this
overall cohort, we screened FUS for mutations in affected indi-
viduals from a further 33 ALS families, as well as the 247
sporadic ALS cases by directly sequencing exons and at least
100 bp of ﬂanking intronic regions. No mutations were identi-
ﬁed in sporadic ALS cases. A missense mutation (accession
NM_004960, c.1562G/A, R521H) was identiﬁed and shown to
segregate with disease in a large multigenerational family
(family ALS2, ﬁgure 1A).
We recruited additional family members to substantially
extend three other families with FUSmutations (families ALS31,
ALS53 and ALS156, ﬁgure 1A) that were in part described previ-
ously.15 FUS mutations segregated with all affected individuals
including three newly recruited ALS cases and an obligate-carrier
(ﬁgure 1B).
Founder haplotype analysis
Linkage analysis in family ALS2 using microsatellite markers
across the FUS locus conﬁrmed that the disease was linked to
the FUS R521H mutation (D16S690 lod¼3.31, D16S753
lod¼3.03, and D16S3044 lod¼3.78; maximum multipoint lod
score¼4.54). Analysis of these microsatellite markers was
undertaken across affected families (ﬁgure 1) to determine
whether those that shared the same mutation were derived
from the same common ancestor (founder effect). Minimum
recombinant haplotypes for these markers were identiﬁed and
compared (table 1). The families that share the R521C mutation
shared no alleles for markers immediately adjacent to FUS,
thereby providing no support for a common ancestor. Families
that share the R521H mutation shared an allele for one marker
(D16S685, allele 3) immediately adjacent to FUS. However, this
shared allele was common in the population (43%).
Illustrative case histories
Patient 1
Individual V-18, family ALS2 (ﬁgure 1 R521H mutation): 59-
year-old woman presented with an 18-month history of
progressive left foot weakness leading to frequent falls. The
weakness progressed to involve proximal muscles in the lower
limbs bilaterally. On examination, cranial nerves were intact.
Upper limbs demonstrated symmetrically normal tone, power
and reﬂexes. In the lower limbs, there was global weakness,
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more marked distally than proximally, with wasting of distal
muscles and fasciculations. Reﬂexes were preserved in the lower
limbs and plantars downgoing. The sensory examination was
normal.
Neurophysiological investigations conﬁrmed normal periph-
eral nerve conduction and reﬂex conduction (H-reﬂexes). F
waves from the lower limbs demonstrated reduced persistence,
consistent with loss of anterior horn cells. Electromyography
demonstrated acute denervation particularly in the lower limbs,
with limited evidence of reinnervation.
MRI scans of the brain and spinal cord conﬁrmed no signiﬁ-
cant structural abnormality. Vasculitic screens were negative.
Lumbar puncture demonstrated a mildly elevated CSF protein of
0.56 g/l (normal 0.15e0.45 g/l) with negative cytology. Oligo-
clonal bands were negative.
Patient 2
From an individual VI-5, family ALS31 (ﬁgure 1, R521C
mutation), a 35-year-old woman initially complained of neck
pain. Three months later, she found that her head lagged when
doing situp exercises. Two months later, she developed weakness
of the right arm and shoulder followed by swallowing difﬁcul-
ties. After choking on food and developing weight loss, a
gastrostomy tube was inserted. When seen 19 months after
ﬁrst symptoms, she had developed ‘dropped head syndrome’ and
required a neck collar to hold her neck up. There was no wasting
of the tongue or bulbar weakness. There was wasting of the
neck and shoulder muscles with neck weakness MRC grade 3/5
and no movement at the shoulders. She could not elevate her
arms above 458. There was antigravity movement at the elbows,
wrists and ﬁngers. She could not sit up. There was MRC grade 4
hip ﬂexion weakness, with normal power at the knees and ankle
joints. The upper-limb reﬂexes were absent, and there were brisk
lower-limb reﬂexes and ﬂexor plantar responses. There was no
sensory loss. Nerve-conduction studies demonstrated normal
sensory responses in the upper and lower limbs. Compound
motor action potentials were of reduced amplitude, without
Table 1 Comparison of chromosome 16 disease haplotypes from
amyotrophic lateral sclerosis (ALS) families with FUS mutations
Mutation R521H Mutation R521C
Marker ALS2 ALS156 ALS31 ALS53 cM Mb
D16S769 X 52.25 26.07
D16S690 289 X X X 56.77 27.87
D16S685 121 121 117 121 58.40 30.58
FUS mutation A A T T 31.11
D16S753 252 260 264 260 58.40 31.18
D16S3044 198 X 198 190 59.06 46.00
D16S541 154 150 150 63.37 49.15
D16S3034 X X X 67.57 51.70
Haplotype alleles are in base pairs.
X denotes an observed recombination event between the indicated marker and the disease
within a family. For each family, the minimal haplotype that segregates with disease is
boxed.
Figure 1 FUS missense mutations in familial amyotrophic lateral sclerosis (ALS). (A) Pedigrees of ALS families that carry the R521H mutation
(families ALS2 and ALS156) and R521C mutation (ALS31 and ALS53). Asterisks indicate DNA available for genotyping. Some individuals in recent
generations have been omitted from the pedigrees for confidentiality. (B) Sequence traces from unaffected control and ALS cases illustrating the
mutations that segregate with disease in these families. The arrowheads indicate the base positions at which FUS is mutated. The codon altered by the
mutation is underlined.
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slowing of motor conduction or evidence of focal motor
conduction block in clinically affected regions.
Clinical features of FUS families
Family ALS2 was of Swedish ancestry, and families ALS31,
ALS53 and ALS156 were of British ancestry. The clinical features
seen in 49 affected individuals from these four families are
described in the online supplementary table. Case histories and
historical notes from families ALS2 and ALS31 are also provided
in the online data supplement. The clinical presentation in all
four families was consistent with a predominantly lower motor
neuron disorder. Head weakness was evident as a common
presenting feature among cases with the R521C mutation but
was only seen as a later feature in one patient with the R521H
mutation. One case in family ALS53 (individual IV-5) had FTD,
and MRI showed atrophy of the frontotemporal regions.
The average age of disease onset in patients with the R521C
and R521H mutations was 42.9 years and 50.7 years respec-
tively, and these were not signiﬁcantly different (p¼0.14). The
average duration of disease in patients with the R521C and
R521H mutation was 1.9 years and 3.0 years respectively, and
these were also not signiﬁcantly different (p¼0.10). There was
a slight observed female bias among patients with FUS muta-
tions, but this was not signiﬁcant (p¼0.50; overall ratio 1.2:1;
ranging from 1.0 to 1.4:1 across the four families).
A degree of non-penetrance of ALS was evident among the
four families, although in some instances, unaffected individuals
who carried a FUS mutation had died before attaining the
average age of onset. The oldest known unaffected individual
who carried a FUS mutation but showed no signs of ALS was
aged 76 years. Ten unaffected individuals in family ALS2 were
mutation carriers (including obligate carriers), and seven of these
carriers were older than the average age of onset (52e76 years).
The age-dependent penetrance of disease for each mutation was
plotted (ﬁgure 2), taking into account the unaffected individuals
who carried a FUS mutation (including obligate carriers) in
each age category. This provided a likelihood estimate that an
individual who carried a mutation would be affected in
a given age range. The age-dependent penetrance distributions
for the two described mutations were signiﬁcantly different
(p¼0.0004). Patients with the R521C mutation were signiﬁ-
cantly more likely to express the disease at a younger age than
those with the R521H mutation.
Assessment of cortical excitability
To clarify the pathophysiological mechanisms of neuro-
degeneration in patients with FUS mutations, assessment of
cortical excitability was undertaken in two representative
patients described earlier (family ALS2 individual V-18; and
family ALS31 individual VI-5).24 In these patients, SICI, deﬁned
as an increase in the test stimulus intensity required to track
a constant target MEP response, was reduced (area under the
curve, 0.3%) when compared with controls (area under the
curve 9.060.8%, p<0.001), although similar when compared
with sporadic ALS patients (0.861.2%) (ﬁgure 3A). Further, the
MEP amplitude, expressed as a percentage of the CMAP ampli-
tude recorded following electrical stimulation, was increased in
the two patients with FUS mutations (53%) when compared
with controls (27.062.2%, 95% CI 22.6 to 31.4%), and again
similar when compared with sporadic ALS patients (4564.4%,
95% CI 36.2 to 54.0%) (ﬁgure 3B).
The cortical silent period, deﬁned as the period of electrical
silence following an MEP response that interferes with ongoing
EMG activity in a contracting muscle, was also assessed. In these
affected patients, the increase in the CSP recruitment curve was
non-linear, similar to the relationship established previously
for sporadic ALS patients.21 25 As stimulus intensity increased
from 60 to 150% RMT, the CSP duration increased from 0 to
121 ms, and was shorter when compared with ALS patients
(0e17568.8 ms, 95% CI 157.4 to 192.6 ms) and controls (0e
208.864.8 ms, 95% CI 199.2 to 218.4 ms). In contrast, RMT,
deﬁned as the unconditioned stimulus intensity required to
produce and maintain the target MEP response, was similar
in all groups (FUS patients, 50%; sporadic ALS 57.961.6%;
controls 60.761.5%) as was the central motor conduction
time (FUS patients, 4.8 ms; sporadic ALS, 5.160.2 ms; controls,
5.160.2 ms).
Pathological features
A post-mortem examination was performed on patient III-2
from family ALS53. The brain was small. No gross lesions
were externally visible or palpable. Coronal sections through
the hemispheres showed no obvious gross abnormalities. The
brainstem and cerebellum also appeared grossly normal. The
spinal cord was small, and the anterior roots were very thin
(sections taken at several levels). Examination of the medulla
conﬁrmed loss of neurons in hypoglossal and dorsal vagal nuclei.
Neurons were sparse in the nucleus ambiguous. Anterior horn
cells were very sparse. There was pallor of lateral and anterior
white-matter columns and of cuneate tract at the upper cervical
level. There was also pallor of lateral white-matter columns at
mid-thoracic level with marked outfall of anterior horn cells.
There were similar appearances in the lumbar cord. Overall, the
appearance was that of progressive muscular atrophy with
terminal bulbar palsy and little evidence of lateral sclerosis. The
cause of death was deﬁned as respiratory failure secondary to
motor neuron disease.
Post-mortem examination was also performed on individual
IV-5 of family ALS53 (the son of the above post-mortem
subject) including immunostaining of brain and spinal cord
tissue. This individual had progressive neurological decline of
Figure 2 Plot of age-dependent penetrance of amyotrophic lateral
sclerosis for individuals with FUS mutations from the four families
shown in figure 1. Data for mutations R521H and R521C are shown in
black and halftone respectively. This provides a likelihood estimate that
an individual who carries a mutation will be affected in a given age
range. The age-dependent penetrance distributions for the R521H and
R521C mutations are significantly different (p¼0.0004).
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2-year disease duration including dysphagia, dystonia, dysarthria,
unsteady gait and complex movement disorder. The spinal cord
showed severe loss of anterior horn cells. There was no evidence
of corticospinal degeneration. The midbrain showed pallor of the
substantia nigra, and microscopic examination revealed severe
loss of pigmented neurons with reactive gliosis. There were no
Lewy bodies or s immunopositive neuroﬁbrillar tangles. The
basal ganglia (globus pallidus, putamen and caudate nuclei)
showed mild neuronal loss and reactive gliosis. TDP-43 immu-
nostains showed normal nuclear staining (ﬁgure 4A) in all
regions analysed including spinal cord segments, midbrain,
medulla, hippocampus, frontal cortex, basal ganglia, subthalamic
nucleus and thalamus. Ubiquitin immunostaining showed
skein-like cytoplasmic staining (ﬁgure 4B) of some anterior
horn cells, hypoglossal neurons, a subset of granule cells of the
dentate gyrus and a small subset of pyramidal cells and neurites
of the frontal cortex. Overall neuropathology established an
unusual motor neuron and nigrostriatal degeneration with
ubiquitin immunostaining (ubiquitinopathy), with no evidence
of TDP-43 proteinopathy.
DISCUSSION
The present series has identiﬁed the key clinical, neurophysio-
logical and pathological ﬁndings across four large ALS kindreds
with FUS mutations, incorporating data from 49 affected
patients. FUS mutations accounted for the disease in 3.2% of
familial ALS across the present cohort and thereby represent the
second most common genetic abnormality to be established in
familial ALS after SOD1. SOD1 mutations were present in
16.9% of families consistent with previous studies of autosomal
Figure 3 Assessment of cortical excitability in amyotrophic lateral
sclerosis (ALS) patients with FUS mutations. (A) Short-interval
intracortical inhibition (SICI), defined as the stimulus intensity required to
maintain a target output. This was reduced in familial ALS patients with
FUS mutations (filled diamonds) when compared with controls (open
boxes). (B) Motor-evoked potential (MEP), expressed as a percentage of
compound muscle action potential (CMAP) amplitude. This was
increased in familial ALS patients with FUS mutations and sporadic ALS
(SALS) patients when compared with controls (Cont).
Figure 4 Immunostaining in FUS linked amyotrophic lateral sclerosis.
(A) Surviving S3 anterior horn cells showing normal TDP-43 nuclear
immunostaining (3200 original magnification). (B) Hypoglossal motor
neuron showing cytoplasmic ubiquitin immunoreactive skein-like
staining (3400 original magnification).
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dominant familial ALS worldwide.8 FUS mutations were
established to be more common than TDP-43 mutations, which
were present in 1.6% of families of the present cohort. The
identiﬁed FUS mutations segregated with disease in each
extended family, and the R521H mutation was strongly genet-
ically linked to the disease in the largest kindred, ALS2. As such,
data from the present series further support the pathogenic role
of FUS mutations in familial ALS. In contrast, no mutations
were identiﬁed in sporadic ALS cases. This is consistent with
previous screens of sporadic ALS cohorts,11 20 although rare
mutations were recently identiﬁed in apparent sporadic cases
from French and French Canadian populations.17
The clinical presentation across all families with FUS muta-
tions was consistent with a predominantly lower motor neuron
disorder, as supported by post-mortem ﬁndings. Nevertheless,
some evidence of upper motor neuron involvement was
provided by electrophysiological data that demonstrated cortical
hyperexcitability, and post-mortem data that identiﬁed corti-
cospinal tract degeneration in one case. In contrast, a second
post-mortem case from the same family showed no corticospinal
tract degeneration, demonstrating that upper motor neuron
involvement is variably associated with FUS-linked ALS. Most
cases (83%) with the R521H mutation had limb-onset disease.
Disease onset associated with the R521C mutation was evenly
distributed between bulbar and limb-onset cases. An inability to
support the head at presentation, or dropped-head syndrome,26
was a frequent feature in families with the R521C mutation.
Despite this, further clinical studies are required to construct
mutation-speciﬁc clinical phenotypes, as currently reported case
numbers remain too small to make deﬁnitive conclusions.
FTD was evident in one individual from the current series.
FTD may be associated with between 3 and 22% of all ALS
cases, and families with comorbid ALS and FTD are increasingly
being recognised,27 with ALS-FTD loci identiﬁed on chromo-
some 9 (reviewed by Neumann et al28). FUS was recently iden-
tiﬁed as the pathological protein in a new subtype of FTD and
neuronal intermediate ﬁlament inclusion disease.29 30 Data from
the present series indicated that FTD may also be a rare
presenting feature associated with FUS mutations.
Reduced disease penetrance was evident across 75% of fami-
lies. Incomplete mutation penetrance tended to be common
among the SOD1-negative families within our overall cohort,
and such families were generally smaller, presumably because of
this fact. Although there was no statistical difference in the
average age of disease onset among the four families, this anal-
ysis only included affected individuals and failed to take into
account the numerous individuals who carried a FUS mutation
but were unaffected (including obligate carriers). By taking into
account these non-penetrant individuals, the present study has
established that patients with the R521C mutation were
signiﬁcantly more likely to develop disease at a younger age.
Assessment of cortical function in ALS patients with FUS
mutations established features indicative of cortical hyperexcit-
ability, similar to changes observed in both familial ALS due to
SOD1 mutations and sporadic ALS patients, including those
with ﬂail limb, lower motor neuron presentations.22 25 31
Together with the post-mortem data, this suggests a ubiquitous
pathophysiological mechanism in ALS and further supports the
hypothesis that a common mechanism underlies the motor
neuron degeneration associated with mutant FUS and abnormal
TDP-43 seen in most sporadic ALS cases.15 16
Consistent with previous ﬁndings,15 post-mortem immunos-
taining in an affected family member with FUS mutation
identiﬁed ubiquitin positive skein-like inclusions in lower motor
neurons, which were not TDP-43 immunoreactive. This
contrasted with sporadic ALS where, for most cases, the hall-
mark cytoplasmic inclusions were immunoreactive for both
TDP-43 and ubiquitin. As such, the disease mechanism under-
lying ALS associated with FUS mutation appears to be inde-
pendent of TDP-43.
Haplotype analysis provided little or no evidence for the
presence of founding mutations (common ancestor) among
the families described in this study. This ﬁnding suggested that
the mutations arose independently, perhaps due to the presence
of a mutation hotspot at residue 521.
The mechanism through which FUS mutations lead to motor
neuron death is unclear. Both FUS and TDP-43 are components
of ribonucleoprotein complexes that regulate tissue-speciﬁc RNA
processing and transport within most cells in the body. In the
affected cells of most ALS cases, TDP-43 redistributes from the
nucleus to the cytoplasm, where it forms aggregates.32 Mutant
FUS has also been shown to redistribute to the cytoplasm and
form aggregates.15 16 It remains unclear whether loss of FUS or
TDP-43 nuclear function leads to motor neuron death, or
whether there is a toxic gain of function in the cytoplasm.
A minority of ALS families carry mutations in SOD1, TARDBP
and FUS. It is likely that many more ALS genes are yet to be
discovered. A challenge for future studies will be to identify the
complex interactions and common molecular pathways that
lead to this devastating disease.
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